248
Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.
 significantly increased risk of DVT: Effect; single-agent thalidomide: Treatment; combination with cytotoxic chemotherapy: Treatment; refractory multiple myeloma (MM): Treatment.Disorder; thalidomide: Treatment.Drug; cytotoxic: Treatment.Drug; chemotherapy: Treatment.Route; thalidomide: Combination.Drug; cytotoxic: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 significantly increased risk of DVT: Effect; single-agent thalidomide: Treatment; combination with cytotoxic chemotherapy: Treatment; refractory multiple myeloma (MM): Treatment.Disorder; thalidomide: Treatment.Drug; cytotoxic: Treatment.Drug; chemotherapy: Treatment.Route; thalidomide: Combination.Drug; cytotoxic: Combination.Drug